Egetis Therapeutics AB (publ) (EGTX.ST)
SEK 6.65
(-8.65%)
SEK 6.65
(-8.65%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 57.6 Million SEK | 156.0% |
| 2022 | 22.5 Million SEK | -41.17% |
| 2021 | 38.24 Million SEK | -5.95% |
| 2020 | 40.66 Million SEK | -50.75% |
| 2019 | 82.56 Million SEK | 192.66% |
| 2018 | 28.21 Million SEK | 107.66% |
| 2017 | 13.58 Million SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | -100.0% |
| 2010 | 2666.00 SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 13.9 Million SEK | 14.88% |
| 2024 Q1 | 12.1 Million SEK | -62.88% |
| 2023 FY | 57.6 Million SEK | 156.0% |
| 2023 Q2 | 5.9 Million SEK | -13.24% |
| 2023 Q1 | 6.8 Million SEK | 21.43% |
| 2023 Q3 | 12.2 Million SEK | 106.78% |
| 2023 Q4 | 32.6 Million SEK | 167.21% |
| 2022 Q1 | 7.1 Million SEK | 121.18% |
| 2022 FY | 22.5 Million SEK | -41.17% |
| 2022 Q4 | 5.6 Million SEK | 9.8% |
| 2022 Q3 | 5.1 Million SEK | 9.44% |
| 2022 Q2 | 4.66 Million SEK | -34.38% |
| 2021 Q2 | 25.03 Million SEK | 561.05% |
| 2021 Q3 | 6.21 Million SEK | -75.19% |
| 2021 Q4 | 3.21 Million SEK | -48.29% |
| 2021 Q1 | 3.78 Million SEK | -22.56% |
| 2021 FY | 38.24 Million SEK | -5.95% |
| 2020 Q2 | 21.48 Million SEK | 83.47% |
| 2020 FY | 40.66 Million SEK | -50.75% |
| 2020 Q4 | 4.89 Million SEK | 90.12% |
| 2020 Q1 | 11.71 Million SEK | -31.32% |
| 2020 Q3 | 2.57 Million SEK | -88.03% |
| 2019 Q1 | 54.9 Million SEK | 394.7% |
| 2019 FY | 82.56 Million SEK | 192.66% |
| 2019 Q2 | 4.43 Million SEK | -91.92% |
| 2019 Q3 | 6.17 Million SEK | 39.08% |
| 2019 Q4 | 17.05 Million SEK | 176.34% |
| 2018 Q3 | 6.71 Million SEK | -30.54% |
| 2018 Q4 | 11.09 Million SEK | 65.27% |
| 2018 FY | 28.21 Million SEK | 107.66% |
| 2018 Q1 | 730 Thousand SEK | -94.63% |
| 2018 Q2 | 9.66 Million SEK | 1224.38% |
| 2017 FY | 13.58 Million SEK | 0.0% |
| 2017 Q4 | 13.58 Million SEK | 0.0% |
| 2017 Q3 | - SEK | -100.0% |
| 2017 Q2 | 144 Thousand SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 Q1 | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 FY | - SEK | -100.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2010 Q2 | 2666.00 SEK | 0.0% |
| 2010 Q1 | - SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2010 FY | 2666.00 SEK | 0.0% |
| 2010 Q3 | - SEK | -100.0% |
| 2009 FY | - SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 0.873% |
| Ziccum AB (publ) | 3.74 Million SEK | -1437.23% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 90.649% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | -14.093% |
| Mendus AB (publ) | 28.48 Million SEK | -102.197% |
| Genovis AB (publ.) | 158.23 Million SEK | 63.598% |
| Intervacc AB (publ) | 8.01 Million SEK | -618.653% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -1216.872% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 66.205% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | -31.219% |
| Aptahem AB (publ) | 2.63 Million SEK | -2089.575% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -5465.217% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -74705.195% |
| Fluicell AB (publ) | 3.33 Million SEK | -1625.584% |
| Saniona AB (publ) | 16.84 Million SEK | -242.043% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | -251.07% |
| Biovica International AB (publ) | 7.29 Million SEK | -690.123% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -4688.03% |
| AcouSort AB (publ) | 10.55 Million SEK | -445.92% |
| Xintela AB (publ) | 78 Thousand SEK | -73746.154% |
| Abliva AB (publ) | 137 Thousand SEK | -41943.796% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -2759.98% |
| OncoZenge AB (publ) | 3000.00 SEK | -1919900.0% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -37061.29% |
| CombiGene AB (publ) | 5.54 Million SEK | -938.939% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 95.227% |
| Camurus AB (publ) | 1.71 Billion SEK | 96.645% |
| Corline Biomedical AB | 25.03 Million SEK | -130.124% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -914.442% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -7888.904% |
| I-Tech AB | 120.86 Million SEK | 52.342% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 57.045% |
| Cyxone AB (publ) | 5.14 Million SEK | -1018.881% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -717.021% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | -440.1% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | -412.909% |
| Nanologica AB (publ) | 1.44 Million SEK | -3891.684% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -108579.245% |
| BioInvent International AB (publ) | 71.46 Million SEK | 19.397% |
| Alzinova AB (publ) | 270 Thousand SEK | -21233.333% |
| Oncopeptides AB (publ) | 35.22 Million SEK | -63.543% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -3837.062% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -1941.106% |
| Simris Alg AB (publ) | 4.35 Million SEK | -1222.921% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -44207.692% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 75.872% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -250334.783% |